相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells
Paul J. Collins et al.
BLOOD (2021)
Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes
Kelsey Pan et al.
LEUKEMIA & LYMPHOMA (2021)
Burkitt Lymphoma International Prognostic Index
Adam J. Olszewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities
Rama Al Hamed et al.
BONE MARROW TRANSPLANTATION (2020)
Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies
Thomas Pincez et al.
HAEMATOLOGICA (2020)
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
Susan Prockop et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting
Jeffrey I. Cohena et al.
LEUKEMIA & LYMPHOMA (2020)
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study
Seok Jin Kim et al.
BLOOD (2020)
CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease
Constanze Slabik et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
Yonggang Pei et al.
CANCERS (2020)
Epstein-Barr Virus: How Its Lytic Phase Contributes to Oncogenesis
Quincy Rosemarie et al.
MICROORGANISMS (2020)
Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation
Amelie Kinch et al.
LEUKEMIA & LYMPHOMA (2019)
Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease
Sajida Kazi et al.
HAEMATOLOGICA (2019)
Novel Therapeutics for Epstein-Barr Virus
Graciela Andrei et al.
MOLECULES (2019)
Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases
Wook Youn Kim et al.
FRONTIERS IN PEDIATRICS (2019)
Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders
Jennifer L. Crombie et al.
FRONTIERS IN ONCOLOGY (2019)
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress
Yasuaki Harabuchi et al.
FRONTIERS IN PEDIATRICS (2019)
Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
Upton D. Allen et al.
CLINICAL TRANSPLANTATION (2019)
PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories
Ana-Iris Schiefer et al.
CANCER MEDICINE (2019)
Latency and lytic replication in Epstein-Barr virus-associated oncogenesis
Christian Muenz
NATURE REVIEWS MICROBIOLOGY (2019)
Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival
Adam X. Sang et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2019)
Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases
Hiroshi Kimura et al.
FRONTIERS IN PEDIATRICS (2019)
Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
Thomas Mika et al.
FRONTIERS IN MEDICINE (2019)
Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience
Cheng-ying Zhu et al.
ANNALS OF TRANSPLANTATION (2019)
How I treat T-cell chronic active Epstein-Barr virus disease
Catherine M. Bollard et al.
BLOOD (2018)
Management of post-transplant lymphoproliferative disorders
Christin B. DeStefano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis
Rebecca A. Marsh
FRONTIERS IN IMMUNOLOGY (2018)
The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis
Abigail Morales-Sanchez et al.
CANCERS (2018)
Epstein–Barr Virus and Cancer
Paul J. Farrell
Annual Review of Pathology-Mechanisms of Disease (2018)
Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program
Barbara Withers et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation
Lauren P. McLaughlin et al.
BLOOD (2018)
Build a Bank: Off-the-Shelf Virus-Specific T Cells
Patrick J. Hanley
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Nivolumab in the Treatment of Hodgkin Lymphoma
Stephen M. Ansell
CLINICAL CANCER RESEARCH (2017)
Post-transplant lymphoproliferative disorder in the pelvis successfully treated with consolidative radiotherapy
Omar Habibeh et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2017)
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation
Ifigeneia Tzannou et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial
Ralf U. Trappe et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review
Garrett K. Berger et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles et al.
ADVANCES IN THERAPY (2017)
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
Bradley M. Haverkos et al.
BLOOD (2017)
EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management
Jorge J. Castillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
Jan Styczynski et al.
HAEMATOLOGICA (2016)
Tumor Regression and Allograft Rejection after Administration of Anti-PD-1
Evan J. Lipson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
Jan Styczynski et al.
HAEMATOLOGICA (2016)
The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment
A. A. Gru et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
The Epstein-Barr virus and the pathogenesis of lymphoma
Martina Vockerodt et al.
JOURNAL OF PATHOLOGY (2015)
Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease
Mark A. Vickers et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant
Rayne H. Rouce et al.
CURRENT OPINION IN HEMATOLOGY (2014)
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
Catherine M. Bollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas
Ulas Darda Bayraktar et al.
LEUKEMIA & LYMPHOMA (2014)
Cytotoxic T lymphocytes for leukemia and lymphoma
Catherine M. Bollard et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Response-Adapted Sequential Immuno-Chemotherapy of Post-Transplant Lymphoproliferative Disorders in Pediatric Solid Organ Transplant Recipients: Results from the Prospective Ped-PTLD 2005 Trial
Britta Maecker-Kolhoff et al.
BLOOD (2014)
EBV-positive diffuse large B-cell lymphoma of the elderly
Chi Young Ok et al.
BLOOD (2013)
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
Ann M. Leen et al.
BLOOD (2013)
Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus-Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
Jan Styczynski et al.
CLINICAL INFECTIOUS DISEASES (2013)
EBV-Related Lymphomas: New Approaches to Treatment
Jennifer A. Kanakry et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2013)
Improving T-Cell Therapy for Epstein-Barr Virus Lymphoproliferative Disorders
Catherine M. Bollard
JOURNAL OF CLINICAL ONCOLOGY (2013)
Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients
Birte Wistinghausen et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2013)
Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies
Zeina Al-Mansour et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Low-Dose Chemotherapy and Rituximab for Posttransplant Lymphoproliferative Disease (PTLD): A Children's Oncology Group Report
T. G. Gross et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
Ekaterina Doubrovina et al.
BLOOD (2012)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Ralf Trappe et al.
LANCET ONCOLOGY (2012)
T-cell therapy in the treatment of post-transplant lymphoproliferative disease
Catherine M. Bollard et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder
R. Reshef et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma
Catherine M. Bollard et al.
CYTOTHERAPY (2011)
A New Model of Epstein-Barr Virus Infection Reveals an Important Role for Early Lytic Viral Protein Expression in the Development of Lymphomas
Shi-Dong Ma et al.
JOURNAL OF VIROLOGY (2011)
T-Cell Therapies for Epstein-Barr Virus-Associated Lymphomas
Javier El-Bietar et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2011)
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
Helen E. Heslop et al.
BLOOD (2010)
Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes
Juliet N. Barker et al.
BLOOD (2010)
Allogeneic T-Cell Therapy for Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease: Long-Term Follow-Up
Tanzina Haque et al.
TRANSPLANTATION (2010)
A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation
Lesley Rees et al.
TRANSPLANTATION (2009)
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor
Aaron E. Foster et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas
Jeffrey I. Cohen et al.
LEUKEMIA & LYMPHOMA (2008)
Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease
Eva Gonzalez-Barca et al.
HAEMATOLOGICA (2007)
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
Tanzina Haque et al.
BLOOD (2007)
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies
Susan R. Perrine et al.
BLOOD (2007)
Treatment of solid organ transplant recipients with autologolus Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)
Barbara Savoldo et al.
BLOOD (2006)
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:: results of a prospective multicenter phase 2 study
S Choquet et al.
BLOOD (2006)
Treatment of PTLD with rituximab or chemotherapy
RL Elstrom et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)
SHK Oertel et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
qRituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation - Results of a phase II trial
AH Blaes et al.
CANCER (2005)
Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation
TG Gross et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-Specific T cells
P Comoli et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Mechanisms of disease - Persistence of the Epstein-Barr virus and the origins of associated lymphomas
DA Thorley-Lawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells
T Haque et al.
LANCET (2002)
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation
JWJ van Esser et al.
BLOOD (2002)
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients
DE Tsai et al.
TRANSPLANTATION (2001)
Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system
KS Slobod et al.
LANCET (2000)
Epstein-Barr virus infection.
JI Cohen
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
